-
-
-
-
-
-
-
Albireo Pharma (ALBO) Announces Expanded Phase 3 Data on Bylvay and A3907 at Upcoming EASL International Liver Congress
-
-
-
-
-
-
-
Albireo Receives Positive CHMP Opinion for Bylvayâ„¢ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
-
-
-
-
-
-
-
Albireo Announces First Patients Dosed in Two New Studies
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

